Skip to content
★ Sign in to follow
SG

Sichuan Goldstone Asia Pharmaceutical Inc. Stock: price and insider trades · China

金石亚药

CN·Mcap CN¥4.9BIndustrials

No insider purchase over the last 90 days. The latest, by 魏宝康, was filed 22 Sept 2022.

Sichuan Goldstone Asia Pharmaceutical Inc.: what insiders have been doing

Every trade that managers of Sichuan Goldstone Asia Pharmaceutical Inc. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Industrials sector. Nothing new has been filed by managers of Sichuan Goldstone Asia Pharmaceutical Inc. in twelve months, the latest record being from 22 September 2022.

Since 2021, the database holds 2 purchases and 1 sale by insiders of the company.

For comparison within the same sector, see the insider buying recorded at Auroora Yhtiöt Oyj and MBB SE. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
3
Thresholds
n/a
Buy Volume
€2M
2 ops. · all time
Sell Volume
€15,097
1 ops. · all time

Since the insiders bought

  • Filed 22 Sept 2022 · 1510 days ago · €121k
    +59.0%
    Entry CN¥7.82 · Close at T+365 CN¥12.43
  • Filed 24 Nov 2021 · 1812 days ago · €2.3M
    +6.0%
    Entry CN¥9.91 · Close at T+365 CN¥10.50

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 10,898 of 26,911 companies
56.4
score / 100
Value
41
Quality
72
FCF yld2.2%
Earn yld2.7%
EV/EBITDA19.3x
ROE6.2%
Gross mgn58%
Net mgn13%
Debt/EBITDA0.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥12.20
Analyst consensus
·
Income statement
RevenueCN¥1B
Gross profitCN¥605.2M58% margin
EBITDACN¥257.4M25% margin
Net incomeCN¥131.6M15.6% margin
Valuation
PER (trailing)30.5x
P/Book1.9x
Beta0.48
Balance sheet & cash
Market capCN¥4.9B
Total debtCN¥76M
Free Cash FlowCN¥108.3M
Debt / Equity4%
Profitability & ownership
ROE6.2%
ROA3.3%
% insiders52.4%
% institutions1.8%
Last declaration on 22 September 2022
Declarations3 total
  • ▲
    董事,高管Executives
    846,312 CNY15SZSE
    107,400 shares88.9% of flowA股XSHESZSE:173000005904269900
    Canonical exit: 21 Dec 2022 (T+90)
  • ▼
    董事长,总裁Executives
    110,000 CNY23SZSE
    10,000 shares11.1% of flowA股XSHESZSE:173000005475184220
  • ▲
    高管Executives
    17M CNY19SZSE
    2,000,000 shares100.0% of flowA股XSHESZSE:173000005106118100
    Canonical exit: 22 Feb 2022 (T+90)

3 of 3 declarations

About Sichuan Goldstone Asia Pharmaceutical Inc.

金石亚药 is a company operating in the industrial sector, specializing in the manufacturing of pharmaceutical products. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations